Mutant p53 targeting by the low molecular weight compound STIMA‐1

H1299 and H1299-His175 cells were seeded in six-well plates with glass slides, 200 000 cells per well. The next day, cells were treated with 2 lM STIMA-1. After 24-h treatment, cells were washed twice in PBS, fixed for 10 min at room temperature with 4% paraformaldehyde (PFA), permeabilized for 2 min in 0.2% Triton in PBS and washed 3 x 5 min in PBS. Anti-Bax antibody SC6236 (Santa Cruz, CA) was diluted 200 times in 2% BSA and incubated with the slides for 2 h at room temperature. After washing 3 9 10 min with PBS, slides were incubated with Alexa Fluor 594 goat anti-rabbit Ig antibody (Invitrogen/Thermo Fisher Scientific, Sweden), diluted 500 times in 2% BSA, for 1 h, then washed 3 9 10 min in PBS and mounted with Vectashield hard set with DAPI (Vector Laboratories, CA). Images were obtained with a Zeiss Axioplan 2 microscope with an AxioCam HRm Camera.

• Publication year

  2017

• Venue

  Molecular Oncology

• Publication date

  2017-05-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1002/1878-0261.12065PMID 28463456PMCID 5527467
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Mutant p53 targeting by the low molecular weight compound STIMA‐1

  2008cited by this paper

• Insight on Heterocycles as p53‐MDM2 Protein‐Protein Interaction Inhibitors: Molecular Mechanism for p53 Activation

  2024cites this paper
• CCT6A promotes cell proliferation in colon cancer by targeting BIRC5 associated with p53 status

  2024cites this paper
• Agents Targeting Apoptosis Take Center Stage in the Battle against Cancer

  2022cites this paper
• Current insights into the regulation of programmed cell death by TP53 mutation in cancer

  2022cites this paper
• Transition of amyloid/mutant p53 from tumor suppressor to an oncogene and therapeutic approaches to ameliorate metastasis and cancer stemness

  2022cites this paper
• TP53 in Biology and Treatment of Osteosarcoma

  2021cites this paper
• Alkaloids of fascaplysin are promising chemotherapeutic agents for the treatment of glioblastoma: Review.

  2020cites this paper
• Improving cancer therapy with new p53-activating agents

  2019cites this paper
• Targeting the Oncogenic p53 Mutants in Colorectal Cancer and Other Solid Tumors

  2019cites this paper
• Design and Synthesis of Novel Inhibitor against Ser121 and Val122 Mutations in P53 Cancer Gene

  2019cites this paper
• Smyd2 conformational changes in response to p53 binding: role of the C‐terminal domain

  2019cites this paper
• Salvation of the fallen angel: Reactivating mutant p53

  2019influential citation
• Understanding p53 structure and targeting mutant p53 for improved cancer therapy

  2018cites this paper
• Advances in sarcoma gene mutations and therapeutic targets.

  2018cites this paper
• Targeting the Prion-like Aggregation of Mutant p53 to Combat Cancer.

  2018cites this paper
• Identification of new inhibitors of Mdm2–p53 interaction via pharmacophore and structure-based virtual screening

  2018cites this paper
• Therapeutic targeting of p53: all mutants are equal, but some mutants are more equal than others

  2018cites this paper
• HDAC inhibitors show differential epigenetic regulation and cell survival strategies on p53 mutant colon cancer cells

  2018cites this paper
• Restoring guardianship of the genome: Anticancer drug strategies to reverse oncogenic mutant p53 misfolding.

  2018cites this paper
• The molecular mechanism of action of methylene quinuclidinone and its effects on the structure of p53 mutants

  2018cites this paper
• Structural and functional consequences of p63 mutations causative of AEC syndrome

  2018cites this paper
• G-actin guides p 53 nuclear transport : potential contribution of monomeric actin in altered localization of mutant p 53

  2017cites this paper
• An in silico approach in predicting the possible mechanism involving restoration of wild-type p53 functions by small molecular weight compounds in tumor cells expressing R273H mutant p53

  2017influential citation
• Correction: Crude Extracts, Flavokawain B and Alpinetin Compounds from the Rhizome of Alpinia mutica Induce Cell Death via UCK2 Enzyme Inhibition and in Turn Reduce 18S rRNA Biosynthesis in HT-29 Cells

  2017cites this paper
• Targeting mutant p53 for efficient cancer therapy

  2017cites this paper
• APR-246 reactivates mutant p53 by targeting cysteines 124 and 277

  2017cites this paper
• The Molecular Basis for Restoring Function to Oncogenic p53 Mutants

  2016cites this paper
• 2-Sulfonylpyrimidines: Mild alkylating agents with anticancer activity toward p53-compromised cells

  2016cites this paper
• Chemical Variations on the p53 Reactivation Theme

  2016cites this paper
• Targeting p53 in cancer: from innovative yeast screening strategies to new drugs

  2016cites this paper
• Piperlongumine exerts cytotoxic effects against cancer cells with mutant p53 proteins at least in part by restoring the biological functions of the tumor suppressor.

  2016cites this paper
• Ranking the Binding Energies of p53 Mutant Activators and Their ADMET Properties

  2015influential citation
• CP-31398 inhibits the growth of p53-mutated liver cancer cells in vitro and in vivo

  2015cites this paper
• Targeting Oncogenic Mutant p53 for Cancer Therapy

  2015cites this paper